Biomarkers and microsatellite instability analysis of curettings can predict the behavior of FIGO stage i endometrial endometrioid adenocarcinoma

Modern Pathology

Volumn 24, Issue 9, 2011, Pages 1262-1271

  Steinbakk, Anita ^a   Malpica, Anais ^b   Slewa, Aida ^a   Skaland, Ivar ^a   Gudlaugsson, Einar ^a   Janssen, Emiel A M ^a   Løvslett, Kjell ^a   Fiane, Bent ^a   Kruse, Arnold Jan ^c   Feng, Weiwei ^d   Yinhua, Yu ^b   Baak, Jan P ^a  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d OBSTETRICS AND GYNECOLOGY HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

Endometrial cancer; FIGO I; microsatellite instability; p21; prognostic; survivin

Indexed keywords

PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; SURVIVIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CURETTAGE; EARLY CANCER; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMAGE CYTOMETRY; MAJOR CLINICAL STUDY; METASTASIS; MICROSATELLITE INSTABILITY; PLOIDY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DILATATION AND CURETTAGE; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; KAPLAN-MEIER ESTIMATE; MICROSATELLITE INSTABILITY; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; ROC CURVE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 80052411397     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.75     Document Type: Article

References (50)

1. Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet 2009;105:109.
2. Baak JP, Snijders W, van Diermen B, et al. Prospective multicenter validation confirms the prognostic superiority of the endometrial carcinoma prognostic index in international Federation of gynecology and obstetrics stage 1 and 2 endometrial carcinoma. J Clin Oncol 2003;21:4214-4221. (Pubitemid 46606191)
3. Van der Putten HW, Baak JP, Koenders TJ, et al. Prognostic value of quantitative pathologic features and DNA content in individual patients with stage I endometrial adenocarcinoma. Cancer 1989;63: 1378-1387. (Pubitemid 19084561)
4. Zaino RJ, Silverberg SG, Norris HJ, et al. The prognostic value of nuclear versus architectural grading in endometrial adenocarcinoma: a Gynecologic Oncology Group study. Int J Gynecol Pathol 1994;13:29-36. (Pubitemid 24006331)
5. Lundgren C, Auer G, Frankendal B, et al. Nuclear DNA content, proliferative activity, and p53 expression related to clinical and histopathologic features in endometrial carcinoma. Int J Gynecol Cancer 2002;12: 110-118. (Pubitemid 34202959)
6. Salvesen HB, Iversen OE, Akslen LA. Prognostic impact of morphometric nuclear grade of endometrial carcinoma. Cancer 1998;83:956-964. (Pubitemid 28401930)
7. Sorbe B, Risberg B, Thornthwaite J. Nuclear morphometry and DNA flow cytometry as prognostic methods for endometrial carcinoma. Int J Gynecol Cancer 1994;4:94-100. (Pubitemid 24179777)
8. Baak JP, Snijders WP, Van Diest PJ, et al. Confirmation of the prognostic value of the ECPI-1 score (myometrial invasion, DNA-ploidy and mean shortest nuclear axis) in FIGO stage I endometrial cancer patients with long follow-up. Int J Gynecol Cancer 1995;5:112-116.
9. Steinbakk A, Skaland I, Gudlaugsson E, et al. The prognostic value of molecular biomarkers in tissue removed by curettage from FIGO stage 1 and 2 endometrioid type endometrial cancer. Am J Obstet Gynecol 2009;200:78 e1-8.
10. Silverberg SG, Kurman RJ, Nogales F, et al. Tumours of the uterine corpus In: Tavassoli FA, Devilee P (eds). Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press: Lyon, 2003, pp 217-228, 219 pp.
11. Jannink I, Bennen JN, Blaauw J, et al. At convenience and systematic random sampling: effects on the prognostic value of nuclear area assessments in breast cancer patients. Breast Cancer Res Treat 1995;36: 55-60.
12. Fleege JC, Baak JP, Smeulders AW. Analysis of measuring system parameters that influence reproducibility of morphometric assessments with a graphic tablet. Hum Pathol 1988;19:513-517.
13. Sorensen FB, Ottosen PD. Stereological estimation of nuclear volume in benign and malignant melanocytic lesions of the skin. Inter-and intraobserver variability of malignancy grading. Am J Dermatopathol 1991; 13:99-107.
14. Mutter GL, Baak JP, Crum CP, et al. Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry. J Pathol 2000;190: 462-469. (Pubitemid 30163587)
15. Soreide K, Slewa A, Stokkeland PJ, et al. Microsatellite instability and DNA ploidy in colorectal cancer: potential implications for patients undergoing systematic surveillance after resection. Cancer 2009;115: 271-282.
16. Suraweera N, Duval A, Reperant M, et al. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 2002;123:1804-1811. (Pubitemid 35408304)
17. Buhard O, Suraweera N, Lectard A, et al. Quasimonomorphic mononucleotide repeats for high-level microsatellite instability analysis. Dis Markers 2004;20: 251-257. (Pubitemid 40164097)
18. Buhard O, Cattaneo F, Wong YF, et al. Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors. J Clin Oncol 2006;24:241-251. (Pubitemid 46622053)
19. Haroske G, Baak JP, Danielsen H, et al. Fourth updated ESACP consensus report on diagnostic DNA image cytometry. Anal Cell Pathol 2001;23:89-95. (Pubitemid 34451106)
20. Baak JP, Bol MG, van Diermen B, et al. DNA cytometric features in biopsies of TaT1 urothelial cell cancer predict recurrence and stage progression more accurately than stage, grade, or treatment modality. Urology 2003;61:1266-1272. (Pubitemid 36694031)
21. Korner H, Soreide K, Stokkeland PJ, et al. Diagnostic accuracy of serum-carcinoembryonic antigen in recurrent colorectal cancer: a receiver operating characteristic curve analysis. Ann Surg Oncol 2007; 14:417-423. (Pubitemid 46175284)
22. Takai N, Miyazaki T, Nishida M, et al. Survivin expression correlates with clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma. Cancer Lett 2002;184:105-116. (Pubitemid 34718112)
23. Salvesen HB, Iversen OE, Akslen LA. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol 1999;17:1382-1390. (Pubitemid 29220843)
24. Ito K, Watanabe K, Nasim S, et al. Prognostic significance of p53 overexpression in endometrial cancer. Cancer Res 1994;54:4667-4670. (Pubitemid 24276491)
25. Nazeer T, Ballouk F, Malfetano JH, et al. Multivariate survival analysis of clinicopathologic features in surgical stage I endometrioid carcinoma including analysis of HER-2/neu expression. Am J Obstet Gynecol 1995;173:1829-1834. (Pubitemid 26005771)
26. Salvesen HB, Das S, Akslen LA. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clin Cancer Res 2000;6:153-159. (Pubitemid 30064988)
27. Engelsen IB, Stefansson I, Akslen LA, et al. Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas. Am J Obstet Gynecol 2006;195:979-986. (Pubitemid 44415644)
28. Stefansson IM, Salvesen HB, Akslen LA. Loss of p63 and cytokeratin 5/6 expression is associated with more aggressive tumors in endometrial carcinoma patients. Int J Cancer 2006;118:1227-1233. (Pubitemid 43185610)
29. Terakawa N, Kanamori Y, Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr Relat Cancer 2003;10:203-208. (Pubitemid 36758649)
30. Uegaki K, Kanamori Y, Kigawa J, et al. PTEN-positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma. Oncol Rep 2005;14:389-392.
31. Athanassiadou P, Athanassiades P, Grapsa D, et al. The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: a prospective immunocytochemical study. Int J Gynecol Cancer 2007;17:697-704. (Pubitemid 46744009)
32. Erkanli S, Kayaselcuk F, Kuscu E, et al. Expression of survivin, PTEN and p27 in normal, hyperplastic, and carcinomatous endometrium. Int J Gynecol Cancer 2006;16:1412-1418. (Pubitemid 43886778)
33. Peiro G, Diebold J, Lohse P, et al. Microsatellite instability, loss of heterozygosity, and loss of hMLH1 and hMSH2 protein expression in endometrial carcinoma. Hum Pathol 2002;33:347-354. (Pubitemid 34461470)
34. Fiumicino S, Ercoli A, Ferrandina G, et al. Microsatellite instability is an independent indicator of recurrence in sporadic stage I-II endometrial adenocarcinoma. J Clin Oncol 2001;19:1008-1014. (Pubitemid 32176275)
35. Honore LH, Hanson J, Andrew SE. Microsatellite instability in endometrioid endometrial carcinoma: correlation with clinically relevant pathologic variables. Int J Gynecol Cancer 2006;16:1386-1392. (Pubitemid 43886774)
36. Wong YF, Ip TY, Chung TK, et al. Clinical and pathologic significance of microsatellite instability in endometrial cancer. Int J Gynecol Cancer 1999;9:406-410.
37. Black D, Soslow RA, Levine DA, et al. Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma. J Clin Oncol 2006;24: 1745-1753. (Pubitemid 46622146)
38. Peiro G, Lohse P, Mayr D, et al. Insulin-like growth factor-I receptor and PTEN protein expression in endometrial carcinoma. Correlation with bax and bcl-2 expression, microsatellite instability status, and outcome. Am J Clin Pathol 2003;120:78-85. (Pubitemid 37046373)
39. An HJ, Kim KI, Kim JY, et al. Microsatellite instability in endometrioid type endometrial adenocarcinoma is associated with poor prognostic indicators. Am J Surg Pathol 2007;31:846-853. (Pubitemid 47165137)
40. MacDonald ND, Salvesen HB, Ryan A, et al. Frequency and prognostic impact of microsatellite instability in a large population-based study of endometrial carcinomas. Cancer Res 2000;60:1750-1752. (Pubitemid 30183451)
41. Zighelboim I, Goodfellow PJ, Gao F, et al. Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. J Clin Oncol 2007;25:2042-2048. (Pubitemid 46972789)
42. Muresu R, Sini MC, Cossu A, et al. Chromosomal abnormalities and microsatellite instability in sporadic endometrial cancer. Eur J Cancer 2002;38:1802-1809.
43. Hirasawa A, Aoki D, Inoue J, et al. Unfavorable prognostic factors associated with high frequency of microsatellite instability and comparative genomic hybridization analysis in endometrial cancer. Clin Cancer Res 2003;9:5675-5682. (Pubitemid 37499490)
44. Ju W, Park HM, Lee SN, et al. Loss of hMLH1 expression is associated with less aggressive clinicopathological features in sporadic endometrioid endometrial adenocarcinoma. J Obstet Gynaecol Res 2006;32: 454-460. (Pubitemid 44410975)
45. Maxwell GL, Risinger JI, Alvarez AA, et al. Favorable survival associated with microsatellite instability in endometrioid endometrial cancers. Obstet Gynecol 2001;97:417-422. (Pubitemid 32184704)
46. Orbo A, Eklo K, Kopp M. A semiautomated test for microsatellite instability and its significance for the prognosis of sporadic endometrial cancer in northern Norway. Int J Gynecol Pathol 2002;21:27-33. (Pubitemid 34008350)
47. Ignatov A, Bischoff J, Ignatov T, et al. APC promoter hypermethylation is an early event in endometrial tumorigenesis. Cancer Sci 2010;101:321-327.
48. Huang YW, Luo J, Weng YI, et al. Promoter hypermethylation of CIDEA, HAAO and RXFP3 associated with microsatellite instability in endometrial carcinomas. Gynecol Oncol 2010;117:239-247.
49. Lagarda H, Catasus L, Arguelles R, et al. K-ras mutations in endometrial carcinomas with microsatellite instability. J Pathol 2001;193:193-199. (Pubitemid 32118131)
50. Ries L, Melbert D, Krapcho M. SEER Cancer Statistics Review, 1975-2005. National Cancer Institute.